Kate Jackson - Dana-Farber Targeted Degradation Webinar Series

Kate Jackson​ - C4 Therapeutics​ “Discovery of CFT8634, a Potent, Selective, and Orally Bioavailable Heterobifunctional Degrader of BRD9”​ #dfci #tpd #brd9 About Dana-Farber Targeted Protein Degradation Webinar Series: Targeted protein degradation (TPD) is a rapidly growing interdisciplinary area of research of both basic science and translational importance. TPD is primarily concerned with the development of agents that induce degradation of protein targets. The precise removal of the target is often linked to a therapeutically beneficial phenotype, making TPD of high interest for drug discovery and development. This webinar series brings together the community of scientists interested in TPD and rapid dissemination of knowledge and best practices. To learn more and join the future webinars please visit: www.danafarbertargetedproteindegradation.org